Recursion
Recursion is a clinical-stage biotechnology company that integrates biology, chemistry, and computer science to industrialize drug discovery. The company utilizes its proprietary Recursion Operating System (OS), an AI-native platform, to map complex biological relationships and design new medicines.
The company focuses on developing a diverse pipeline of investigational medicines, primarily in the fields of oncology and rare diseases. Its internal programs include treatments for familial adenomatous polyposis (FAP), solid tumors, and lymphoma. Recursion's approach involves generating massive proprietary datasets—exceeding 50 petabytes—to train foundation models that predict how different molecules will interact with cellular biology, thereby de-risking the drug discovery process.
Recursion operates through a "lab-in-the-loop" system, where physical experiments are converted into digital data to continuously improve its predictive algorithms. This integrated engine allows the company to move rapidly from target identification to clinical development. In addition to its internal pipeline, Recursion collaborates with major pharmaceutical and technology partners to explore disease domains such as neuroscience and immunology.
Headquartered in Salt Lake City, Utah, Recursion maintains additional research hubs and offices in Montreal, Toronto, London, and Oxford. The company employs a multidisciplinary team of scientists and technologists dedicated to its mission of decoding biology to improve human health.
- Headquarters
- Salt Lake City, Utah, United States
- Founded
- 2013
- Type
- Public company
- Website: recursion.com
Industries: Biotechnology, Pharmaceuticals
Categories: Drug Discovery, Machine Learning
AntSpace put this profile together from public information. It may be incomplete; once Recursion claims it, its admins can edit everything here.
Our mission
Recursion's mission is to decode biology to radically improve lives.
Our vision
Recursion is building a future where biology is solvable by industrializing drug discovery through automation, algorithms, and data.
Our culture
Recursion describes its culture as a strategic differentiator, guided by a mindset that disrupts the status quo and guards against complacency. The company values cross-functional collaboration, where teams of life scientists and technologists—referred to as "Recursionauts"—work together as "One Recursion." This environment prioritizes trust, clarity, and humility, encouraging employees to take calculated risks and act boldly with integrity. The company emphasizes active learning and rapid adaptation, valuing experimentation and iteration over perfection. Inclusion and belonging are central to the culture, supported by various employee resource groups and professional development resources. Recursion also maintains a commitment to transparency and accountability, where leaders take decisive action and teams own outcomes together.
Core values
- We act boldly with integrity.
- We move with urgency because patients are waiting.
- We care deeply and engage directly.
- We take ownership and accountability.
- We learn actively and adapt rapidly.
- We are One Recursion.
Specialties
- AI-enabled drug discovery
- Machine learning foundation models
Markets served
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Oncology
- Rare Disease
- Neuroscience
- Immunology
Key facts
- Legal name
- Recursion Pharmaceuticals, Inc.
- Countries
- 3
- Stock listing
- NASDAQ: RXRX
- Public since
- 2021
Latest from Recursion
- Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration (Partnership · October 15, 2026)
Sanofi exercised an option to advance a potential first-in-class small molecule candidate from its collaboration with Recursion. The drug is designed to target inflammatory diseases and is expected… - Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone (Project update · October 15, 2026)
Recursion shared positive Phase 2 results for REC-4881, an investigational treatment for familial adenomatous polyposis. The data showed significant reductions in polyp burden across the…
Products by Recursion
- LOWE (Developer tool)
Proprietary drug discovery software for navigating biological and chemical complexity.
AI models by Recursion
- MolPhenix (Science / biology model)
Learning the effects of molecules on cells with phenomic AI
AI agents by Recursion
- Patience (Research agent)
An agentic system for performing scientific literature review
Clients and partners
4 clients and partners
Upcoming events
- Evercore 9th Annual Healthcare Conference (Conference · November 30, 2026)
- Citi’s 2026 Global Healthcare Conference (Conference · December 1, 2026)
Documents
2 documents
Locations
- Headquarters · Salt Lake City, United States (headquarters)
6 more products, services and AI on AntSpace. Sign up free to see the full catalog.
Leadership, clients, case studies, documents and every location on AntSpace. Sign up free to see them.